Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Non Operating Income: 2013-2025

Historic Other Non Operating Income for Ocular Therapeutix (OCUL) over the last 8 years, with Sep 2025 value amounting to -$938,000.

  • Ocular Therapeutix's Other Non Operating Income was N/A to -$938,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.7 million, marking a year-over-year change of. This contributed to the annual value of -$27.9 million for FY2024, which is 296.97% down from last year.
  • As of Q3 2025, Ocular Therapeutix's Other Non Operating Income stood at -$938,000, which was down 445.35% from -$172,000 recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Other Non Operating Income ranged from a high of $25.0 million in Q1 2021 and a low of -$62.2 million during Q4 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was -$172,000 (2025), whereas its average is -$2.0 million.
  • Per our database at Business Quant, Ocular Therapeutix's Other Non Operating Income skyrocketed by 1,418,900.00% in 2023 and then slumped by 2,794,900.00% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Other Non Operating Income (Quarterly) stood at -$62.2 million in 2021, then crashed by 100.00% to $1,000 in 2022, then skyrocketed by 1,418,900.00% to $14.2 million in 2023, then crashed by 2,794,900.00% to -$27.9 million in 2024, then surged by 97.83% to -$938,000 in 2025.
  • Its Other Non Operating Income stands at -$938,000 for Q3 2025, versus -$172,000 for Q2 2025 and -$606,000 for Q1 2025.